Payment overview · 2025
General Payments
$551.85
34 reported records · 8 companies
Healthcare provider profile · identity verified
Maureen Rose Lannan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SULPHUR, LA · NPI 1023014313
Verified facts
What the public records show
CMS Open Payments records show Maureen Rose Lannan, M.D. received $551.85 in general payments during 2025 across 34 reported records.
Novo Nordisk Inc accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $171.27 | 31.0% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.59 | 25.8% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $101.84 | 18.4% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.95 | 8.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.05 | 5.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.26 | 4.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.59 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.30 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $551.85 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $85.88 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.39 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $75.94 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $66.65 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.65 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $54.38 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.95 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.21 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 123 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
123 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 532 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 54 |
| Potassium Chloride | Potassium Chloride | 213 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 170 | 44 |
| Prednisone | Prednisone | 170 | 113 |
| Trazodone Hcl | Trazodone Hcl | 170 | 42 |
| Losartan Potassium | Losartan Potassium | 166 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 45 |
| Alprazolam | Alprazolam | 151 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 41 |
| Gabapentin | Gabapentin | 143 | 39 |
| Furosemide | Furosemide | 139 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 131 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 23 |
| Omeprazole | Omeprazole | 126 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 32 |
| Mounjaro | Tirzepatide | 123 | 19 |
| Ozempic | Semaglutide | 116 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 21 |
| Pregabalin | Pregabalin | 102 | 22 |
| Sertraline Hcl | Sertraline Hcl | 102 | 22 |
| Atenolol | Atenolol | 95 | 26 |
| Metformin Hcl Er | Metformin Hcl | 94 | 27 |
| Estradiol | Estradiol | 91 | 19 |
| Clonazepam | Clonazepam | 88 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 69 |
| Temazepam | Temazepam | 85 | 11 |
| Eliquis | Apixaban | 80 | 17 |
| Lisinopril | Lisinopril | 80 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 22 |
| Montelukast Sodium | Montelukast Sodium | 77 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 15 |
| Labetalol Hcl | Labetalol Hcl | 73 | 20 |
| Alendronate Sodium | Alendronate Sodium | 67 | 19 |
| Synthroid | Levothyroxine Sodium | 67 | 18 |
| Lovastatin | Lovastatin | 63 | 15 |
| Allopurinol | Allopurinol | 61 | 16 |
| Memantine Hcl | Memantine Hcl | 61 | 14 |
| Meloxicam | Meloxicam | 58 | 15 |
| Metformin Hcl | Metformin Hcl | 58 | 15 |
| Warfarin Sodium | Warfarin Sodium | 57 | 13 |
| Azelastine Hcl | Azelastine Hcl | 54 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 51 | suppressed |
| Glimepiride | Glimepiride | 51 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 11 |
| Simvastatin | Simvastatin | 45 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 29 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 12 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 34 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Armodafinil | Armodafinil | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $551.85 · 34 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, EVENITY, FARXIGA, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error